What is Opus Genetics's G&A?

Opus Genetics (IRD) reported G&A of $5.94M in Q1 2026.

How has Opus Genetics's G&A changed year-over-year?

Opus Genetics's G&A decreased by 6.3% year-over-year, from $6.35M to $5.94M.

What is the long-term trend for Opus Genetics's G&A?

Over 4 years (2021 to 2025), Opus Genetics's G&A has grown at a 28.3% compound annual growth rate (CAGR), from $8.12M to $21.98M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Opus Genetics IRD G&A

G&A at other companies

MeiraGTx Holdings plcMGTX

$8.93M-4.7%

4D Molecular TherapeuticsFDMT

$11.69M-9.7%

Kodiak Sciences IncKOD

$11.23M-27.2%

RegenxbioRGNX

$21.31M+4.7%

Prime MedicinePRME

$17.41M+31.0%

Candel Therapeutics, Inc.CADL

$6.44M+56.6%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's G&A?: Opus Genetics (IRD) reported G&A of $5.94M in Q1 2026.
How has Opus Genetics's G&A changed year-over-year?: Opus Genetics's G&A decreased by 6.3% year-over-year, from $6.35M to $5.94M.
What is the long-term trend for Opus Genetics's G&A?: Over 4 years (2021 to 2025), Opus Genetics's G&A has grown at a 28.3% compound annual growth rate (CAGR), from $8.12M to $21.98M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.